Search
Thiabendazole
go.drugbank.com/drugs/DB00730ApprovedVet approvedWithdrawn2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. It has CNS side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of P...
Sitimagene ceradenovec
go.drugbank.com/drugs/DB04907ExperimentalIt is being developed by Ark Therapeutics.
ORG-34517
go.drugbank.com/drugs/DB05423InvestigationalORG-34517 is currently under investigation by Organon for the treatment of depression.
Imlifidase
go.drugbank.com/drugs/DB15258ApprovedInvestigational[A225836,A225921] Imlifidase is a cysteine protease and eliminates Fc-dependent effector functions such as CDC and ADCC by cleaving the heavy chains of human immunoglobulin G (IgG) antibodies.
Conestat alfa
go.drugbank.com/drugs/DB09228ApprovedDown-stream effects of the lack of enzyme inhibition by C1 esterase inhibitor results in swelling due to leakage of fluid from blood vessels into connective tissue and consequently the presentation of
Products: RUCONEST 2100 U IV ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ İÇEREN FLAKON, 1 ADETOsemozotan
go.drugbank.com/drugs/DB05339ExperimentalMN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD)
Sonrotoclax
go.drugbank.com/drugs/DB18753ApprovedInvestigationalIt promotes tumor cell survival by sequestering proapoptotic proteins and blocking the intrinsic mitochondrial apoptotic pathway.
Geraniol
go.drugbank.com/drugs/DB14183ApprovedIt is emitted from the flowers of many species of plant and is commonly used by the food, fragrance, and cosmetic industry[L3333]. … These pharmacologic effects are clinically important as geraniol is classified as generally-recognized-as-safe (GRAS) by the Flavor and Extract Manufacturers Association (FEMA) and the Food and Drug Administration
Gedatolisib
go.drugbank.com/drugs/DB11896ApprovedInvestigational[L63927] Its approval also addresses a population defined by the absence of a biomarker, as patients with PIK3CA wild-type disease were not eligible for the PI3Kα-selective options. … [L63927] Gedatolisib was approved by the FDA on July 14, 2026, in combination with [fulvestrant], with or without [palbociclib], for adults with HR-positive, HER2-negative locally advanced or metastatic
Adipiplon
go.drugbank.com/drugs/DB06579InvestigationalAdipiplon is an nonbenzodiazepine anxiolytic developed by Neurogen Corporation. It is known by the standardized identifier NG2-73.